The United States Drug Allergy Registry (USDAR) is a multi-center longitudinal prospective cohort, run by a team of allergists dedicated to improving clinical care while promoting public health and scientific discovery though improving the evaluation and management of drug allergies, particularly penicillin (PCN) allergies.

Our team convened in 2017 and began enrolling patients in 2019. We currently have patients enrolled from 3 sites with diverse drug allergy histories. We are always open to meeting with potential new collaborators.

Many of our patients have a reported PCN allergy when they come to our clinics. Approximately 30 million Americans believe they have a PCN allergy but most of these patients can safely tolerate PCNs and other beta-lactam antibiotics. Reported PCN allergies result in the use of less effective and broader-spectrum antibiotics, increasing risk of treatment failures and healthcare-associated infections, including Clostridiodes difficile and death. We perform testing for PCN allergy and follow important individual and public health outcomes over time.

Almost 60% of our enrolled patients have reported allergies to other drugs, including: other antibiotics, non-steroidal anti-inflammatory agents (NSAIDs), anesthetics, opioids, steroids, vaccines, and chemotherapeutics.  Many of these patients will receive testing for their drug allergies with important outcomes also followed over time.

USDAR data are observational, derived from patient-reported data, clinical documentation, and electronic health records.